-Reuters
https://www.reuters.com/technology/exclusive-chinas-catl-slows-battery-investment-plan-us-mexico-sources-2022-10-21/
AbbVie Reports FDA Granted Breakthrough Therapy Designation To Telisotuzumab Vedotin For Previously-Treated Non-Small Cell Lung Cancer
LUMINOSITY (M14-239) is ongoing, and the Phase 3 study TeliMET NSCLC-01 (M18-868) is planned to begin in the first half of 2022
- There are currently no approved cancer therapies specifically for patients with c-Met
